Page "Antipsychotic" Paragraph 43

Nevertheless, a 2009 systematic review and meta-analysis of trials in people diagnosed with schizophrenia found that less than half ( 41 %) showed any therapeutic response to an antipsychotic, compared to 24 % on placebo, and that there was a decline in treatment response over time, and possibly a bias in which trial results were published.

In addition, a 2010 Cochrane Collaboration review of trials of Risperidone, one of the biggest selling antipsychotics and the first of the new generation to become available in generic form, found only marginal benefit compared with placebo and that, despite its widespread use, evidence remains limited, poorly reported and probably biased in favor of risperidone due to pharmaceutical company funding of trials.

Another Cochrane review in 2009, of bipolar disorder, found the efficacy and risk / benefit ratio better for the traditional mood stabilizer lithium than for the antipsychotic Olanzapine as a first line maintenance treatment.